Emcure Pharmaceuticals Limited
EMCURE · NSE · ₹1,937 a share (close of 05 Oct 2026)
Available company data, source links and archived checks for Emcure Pharmaceuticals Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Revenue rose 22.8%; Net profit was ₹292.49 crore.
Quarter ended 2026-06-30 · consolidated · Company filing
Recorded quarterly figures
| Quarter | Revenue / income | YoY |
Profit | YoY | Net margin | Source |
|---|
| Jun 2026 | Revenue: ₹2,580 cr | +22.8% | Net profit: ₹292 cr | +36.2% | 11.3% | Company filing source |
| Mar 2026 | Revenue: ₹2,470 cr | +16.7% | Net profit: ₹244 cr | +23.6% | 9.9% | Company filing source |
| Dec 2025 | Revenue: ₹2,363 cr | — | Net profit: ₹231 cr | — | 9.8% | Company filing source |
| Sep 2025 | Revenue: ₹2,270 cr | — | Net profit: ₹251 cr | — | 11.1% | Company filing source |
| Jun 2025 | Revenue: ₹2,101 cr | +15.7% | Net profit: ₹215 cr | +40.8% | 10.2% | Company filing source |
| Mar 2025 | Revenue: ₹2,116 cr | — | Net profit: ₹197 cr | — | 9.3% | Company filing source |
YoY means change from the same quarter a year earlier.
— means no comparable figure is available. Older entries with incomplete source
details have not been revalidated under the current checks.
Recently checked facts
CARE Ratings reaffirmed Emcure's credit rating at CARE AA; Stable with a CARE A1+ short-term rating in September 2026.
Net profit for the June quarter grew 36.2% from the same quarter a year earlier.
Promoters held 77.83% of the company as of June 2026.
Revenue for the June quarter grew 22.8% from the same quarter a year earlier.
Who holds it — from the filings
Satish R Mehta 39.8%Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees) 7.7%Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees) 7.7%Samit Satish Mehta 7.1%Bhavana Satish Mehta 4.7%register as filed
2026-06-30
Filing timeline — what the company told the exchange
- Emcure Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company…
02 Oct 2026 · document
- Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201…
29 Sep 2026 · document
- Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation…
25 Sep 2026 · document
- General Updates. EMCURE: Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company.…
23 Sep 2026 · document
- Shareholders meeting. Emcure Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 21, 2026. …
23 Sep 2026 · document
- Shareholders meeting. Emcure Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 21, 2026…
21 Sep 2026 · document
- ESOP/ESOS/ESPS. Emcure Pharmaceuticals Limited has informed the Exchange regarding Allotment of 11400 Shares.…
11 Sep 2026 · document
- General Updates. Intimation under Regulations 30 and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dispatch of letter…
01 Sep 2026 · document
Follow this company without reading every document yourself.
Keep its available filings, dated fact checks and disclosure alerts together.
Your saved country sets your market and its research schedule.
Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment
advice · cancel any time